Literature DB >> 8298772

Physiologic measures: pulmonary function tests. Asthma outcome.

P L Enright1, M D Lebowitz, D W Cockroft.   

Abstract

When the effectiveness of asthma interventions are evaluated in the research setting, the physiologic manifestation of asthma-variable airways obstruction-is always objectively measured by some of the following pulmonary function tests: (1) Baseline spirometry gives a highly accurate "snapshot" of asthma severity and the degree of airways obstruction. The FEV1, derived from spirometry, is the most reproducible pulmonary function parameter and is linearly related to the severity of airways obstruction. There are no contraindications for the test, spirometers are widely available at reasonable cost, and methods and result interpretation are comprehensively standardized. (2) The post-bronchodilator FEV1 measures the best lung function that can be achieved by bronchodilator therapy on the day of the visit and therefore is a more stable measure in asthmatics than comparing visit-to-visit baseline FEV1. Although a positive acute response to bronchodilator helps to confirm the diagnosis of asthma, the degree of bronchodilator reversibility from visit-to-visit (change in reversibility) is not a useful index of asthma outcome. (3) Airway responsiveness (bronchial challenge) measures the degree to which an individual withstands nonspecific stimuli that trigger asthmatic attacks. The methacholine challenge test is safe and requires less than an hour, but it requires more technical skill than baseline spirometry and is contraindicated in some situations. (4) Ambulatory monitoring, using peak flow meters or hand-held spirometers, provides multiple measurements of the degree of obstruction for days to weeks in the patient's natural setting. PEF meters are very inexpensive and almost all asthmatics can use them, but PEF results are less reliable than the FEV1. The often asymptomatic obstruction of an asthmatic has both short-term (within a day and day-to-day) and longer-term variations that are triggered by naturally occurring stimuli. These changes are measured by PEF lability but not by spirometry during clinic visits. (5) Other pulmonary function tests, such as absolute lung volumes and airways resistance, may provide confirmatory data, but the instruments are large, expensive, and technically demanding. The results of all the above pulmonary function tests are significantly correlated with each other and with symptom scores and medication use in large groups of patients with widely varying degrees of asthma severity. Since a "gold standard" with which to measure asthma severity does not currently exist, all of these tests contribute an additional amount of unique information when measuring asthma outcome in a clinical trial.

Entities:  

Mesh:

Year:  1994        PMID: 8298772     DOI: 10.1164/ajrccm/149.2_Pt_2.S9

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  25 in total

1.  Asthma outcome measures.

Authors:  K D Watkins
Journal:  J Med Syst       Date:  1999-08       Impact factor: 4.460

Review 2.  Pharmacologic management of the hospitalized pediatric asthma patient.

Authors:  K A Hardin; H J Kallas; R J McDonald
Journal:  Clin Rev Allergy Immunol       Date:  2001-06       Impact factor: 8.667

3.  Fuzzy rule-based expert system for assessment severity of asthma.

Authors:  Maryam Zolnoori; Mohammad Hossein Fazel Zarandi; Mostafa Moin; Shahram Teimorian
Journal:  J Med Syst       Date:  2010-12-03       Impact factor: 4.460

Review 4.  The pharmacogenetics of asthma treatment.

Authors:  Kelan Tantisira; Scott Weiss
Journal:  Curr Allergy Asthma Rep       Date:  2009-01       Impact factor: 4.806

5.  Thymic stromal lymphopoietin and the pathophysiology of atopic disease.

Authors:  Michael M Miazgowicz; Mark B Headley; Ryan P Larson; Steven F Ziegler
Journal:  Expert Rev Clin Immunol       Date:  2009-09-01       Impact factor: 4.473

6.  Modeling asthma exacerbations through lung function in children.

Authors:  Ann Chen Wu; Martin Gregory; Steven Kymes; Dennis Lambert; Joshua Edler; Dustin Stwalley; Anne L Fuhlbrigge
Journal:  J Allergy Clin Immunol       Date:  2012-09-27       Impact factor: 10.793

7.  Admixture-matched case-control study: a practical approach for genetic association studies in admixed populations.

Authors:  Hui-Ju Tsai; Jennifer Y Kho; Nishat Shaikh; Shweta Choudhry; Mariam Naqvi; Daniel Navarro; Henry Matallana; Richard Castro; Craig M Lilly; H George Watson; Kelley Meade; Michael Lenoir; Shannon Thyne; Elad Ziv; Esteban González Burchard
Journal:  Hum Genet       Date:  2005-11-05       Impact factor: 4.132

8.  Beta 2-adrenergic receptor polymorphisms: pharmacogenetic response to bronchodilator among African American asthmatics.

Authors:  Hui-Ju Tsai; Nishat Shaikh; Jennifer Y Kho; Natalie Battle; Mariam Naqvi; Daniel Navarro; Henry Matallana; Craig M Lilly; Celeste S Eng; Gunjan Kumar; Shannon Thyne; H George Watson; Kelley Meade; Michael LeNoir; Shweta Choudhry; Esteban G Burchard
Journal:  Hum Genet       Date:  2006-04-05       Impact factor: 4.132

9.  Asthma in children of Caribbean descent living in the inner-city: comparing Puerto Rican and Afro-Caribbean children.

Authors:  Dara M Steinberg; Denise Serebrisky; Jonathan M Feldman
Journal:  Psychol Health Med       Date:  2016-09-25       Impact factor: 2.423

10.  Single breath counting for the evaluation of pediatric respiratory function: derivation of a "normogram".

Authors:  Lawrence Edward Kass; Kristy Putnam
Journal:  Intern Emerg Med       Date:  2015-09-28       Impact factor: 3.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.